Skip to main content

Table 3 Subjects experiencing at least one adverse event likely due to study treatment, by study arm

From: An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study

Experienced an adverse event

Randomised Group

Intervention

Standard

Total

No

23

20

43

Yes

4 (14.8%)

5 (20.0%)

9

Total

27

25

52